Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
D2DR/Dopamine D2 Receptor CRISPR Activation Plasmid (h): sc-400235-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- D2DR/Dopamine D2 Receptor CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- D2DR/Dopamine D2 Receptor CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by D2DR/Dopamine D2 Receptor CRISPR Activation Plasmid (h) and D2DR/Dopamine D2 Receptor CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the DRD2 transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: D2DR/Dopamine D2 Receptor Antibody (B-10): sc-5303
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
D2DR/Dopamine D2 Receptor CRISPR Activation Plasmid (h) | sc-400235-ACT | 20 µg | $397.00 |
DRD2 encodes the dopamine D2 receptor (D2DR), a Gi/o-coupled GPCR that regulates neurotransmission by inhibiting adenylyl cyclase, reducing cAMP/PKA signaling, and modulating ion channel activity. D2DR signaling influences synaptic plasticity and neuronal excitability and interfaces with MAPK/ERK and β-arrestin–mediated pathways that shape receptor desensitization and trafficking. In the central nervous system, DRD2 is a key node in dopaminergic circuits controlling motivation, reward processing, and motor function. Altered DRD2 expression or signaling has been implicated in neuropsychiatric and movement-disorder biology, supporting its use as a mechanistic target in pathway mapping and functional genomics studies.
D2DR/Dopamine D2 Receptor CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous DRD2 expression without altering the underlying DNA sequence.
D2DR/Dopamine D2 Receptor CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the DRD2 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the DRD2 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous D2DR/Dopamine D2 Receptor expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native DRD2 locus and enabling the study of D2DR/Dopamine D2 Receptor-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of D2DR/Dopamine D2 Receptor pathway restoration in tumor cells with silenced or reduced DRD2 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.